French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) said on Wednesday that it has committed an additional USD625m to Sanofi Ventures, its corporate venture capital arm, increasing its total assets under management to over USD1.4bn.

The multi-year investment will focus on early-stage biotech and digital health companies in immunology, rare diseases, neurology, and vaccines.

Since its founding in 2012, Sanofi Ventures has deployed more than USD800m across over 70 companies, participating in private financing rounds, board activities, and IPOs. The fund invests globally across all stages of the private company lifecycle, from seed to crossover, supporting innovation that aligns with Sanofi's long-term strategy.

The additional capital reinforces Sanofi's commitment to fostering pioneering healthcare solutions and advancing technologies that transform patient care.